Intellia Therapeutics to Highlight Ex Vivo Genome Editing and CRISPR/Cas9 Manufacturing Advances at 2021 American Society of Hematology (ASH) Annual Meeting
05 nov. 2021 07h30 HE
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using...
Global $8.7 Bn Genome Editing Markets to 2026: Focus on CRISPR, TALENs, Zinc Finger Nucleases, Cell Line Engineering, Animal Genetic Engineering
23 sept. 2021 04h08 HE
|
Research and Markets
Dublin, Sept. 23, 2021 (GLOBE NEWSWIRE) -- The "Global Genome Editing Market, By Technique (CRISPR, TALENs, Zinc Finger Nucleases, Others), By Application (Cell Line Engineering, Animal Genetic...
Global CRISPR Markets, 2021-2026 - Rapid Increase in Genetic Disorders to Expand Market Demand
21 sept. 2021 03h48 HE
|
Research and Markets
Dublin, Sept. 21, 2021 (GLOBE NEWSWIRE) -- The "CRISPR Market - Forecasts from 2021 to 2026" report has been added to ResearchAndMarkets.com's offering. The global CRISPR market is evaluated at...
Metagenomic Sequencing Market size worth $ 1,353.28 Million, Globally, by 2028 at 6.35% CAGR: Verified Market Research®
10 août 2021 09h15 HE
|
Verified Market Research
Jersey City, New Jersey, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Verified Market Research recently published a report, “Metagenomic Sequencing Market” By Workflow (Sequencing, Data Processing and...
Global Oligonucleotide Synthesis Market Report 2021: Market is Poised for Explosive Growth as Gene Technology Moves into Mainstream Healthcare, Food Production and, Even, Data Storage
03 août 2021 06h58 HE
|
Research and Markets
Dublin, Aug. 03, 2021 (GLOBE NEWSWIRE) -- The "Oligonucleotide Synthesis Markets - Forecasts by Oligo Length, Application, and Product - With Executive and Consultant Guides and including Customized...
Global $34.31 Billion Cell and Gene Therapy Markets, 2015-2020, 2025F, 2030F
12 juil. 2021 04h38 HE
|
Research and Markets
Dublin, July 12, 2021 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapy market Global Market Opportunities and Strategies to 2030: COVID-19 Growth and Change" report has been added to...
Intellia and Regeneron Announce Landmark Clinical Data Showing Deep Reduction in Disease-Causing Protein After Single Infusion of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis
26 juin 2021 11h15 HE
|
Intellia Therapeutics, Inc.
First-ever clinical data supporting safety and efficacy of in vivo CRISPR genome editing in humans Interim readout in ongoing Phase 1 trial finds single 0.3 mg/kg dose of NTLA-2001 led to 87% mean...
North America Cell Therapy (Allogeneic and Autologous) Market Report 2021-2027
25 juin 2021 06h13 HE
|
Research and Markets
Dublin, June 25, 2021 (GLOBE NEWSWIRE) -- The "North America Cell Therapy Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Therapy Type, Product, Technology, Application, and End...
CRISPR and Cas Genes Markets, 2028 by Product & Service (Vector-based Cas, DNA-free Cas), Application (Biomedical, Agriculture)
16 juin 2021 06h08 HE
|
Research and Markets
Dublin, June 16, 2021 (GLOBE NEWSWIRE) -- The "CRISPR and Cas Genes Market Size, Share & Trends Analysis Report by Product & Service (Vector-based Cas, DNA-free Cas), by Application...
Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2021 Peripheral Nerve Society Annual Meeting
04 juin 2021 07h30 HE
|
Intellia Therapeutics, Inc.
Data to offer insight into safety and pharmacodynamics of NTLA-2001, the first-ever systemically administered in vivo CRISPR therapy candidateLate-breaking abstract selected for oral presentation on...